Tremfya
Johnson & Johnson’s arthritis drug shows promising results in Phase III trial
March 16, 2021Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.
European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo
December 2, 2020Research and Development, Sales and Marketing Europe, Janssen, Tremfya
The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …
CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis
October 19, 2020Sales and Marketing CHMP, EMA, Janssen, Tremfya
Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …
Jannsen’s Tremfya becomes first FDA-approved IL-23 inhibitor for active psoriatic arthritis
July 15, 2020Research and Development, Sales and Marketing FDA, Jannsen, Tremfya, active psoriatic arthritis
Janssen has reported that its therapy Tremfya (guselkumab) has become the first selective interleukin (IL)-23 inhibitor approved by the FDA …
Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says
June 15, 2020Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis
Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual …
Janssen’s Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies
June 4, 2020Research and Development Janssen, Tremfya, psoriatic arthritis
Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in …
Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis
August 15, 2019Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis
Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …
Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis
October 22, 2018Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis
Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …
Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis
September 13, 2018Research and Development Humira, Janssen, Tremfya, pharma, psoriasis
Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …
Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis
May 11, 2018Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis
NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …
Top Ten most popular articles on Pharmafile.com this week
February 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease
It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
J&J uses FDA Priority Review Voucher to snag psoriasis approval
July 14, 2017Medical Communications, Sales and Marketing Janssen, Johnson & Johnson, Tremfya, biotech, drugs, pharma, pharmaceutical
The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this …
